Russian Pharma Sector Analysis (2007)

Publication Date	August 2007
Publisher	RNCOS
Product Type	Report
Pages	90
ISBN Number	not applicable
Product Code	RCS00216

Price

£625.00
approximately: $1,104 | €793

PDF

PRINT £795 ($1,404 | €1,008)

CD-ROM £795 ($1,404 | €1,008)

Order above formats by FAX

Summary

The RNCOS report - "Russian Pharma Sector Analysis (2007)" - provides an extensive research and objective analysis on the growing demand of pharmaceuticals in Russia and presents a clear picture of the country's healthcare and pharmaceutical market.

The Russian pharmaceutical market, in 2006, witnessed one of the strongest growths globally with both the state and commercial segments registering double-digit growth in their sales value. The major impetus for growth was given by the Government's Drug reimbursement programme, which saw the consumption value of drugs increased by nearly 74% in 2006.

The commercial drugs market, driven by factors such as an ageing population, an increasing demand for imported and expensive medicines, an obligatory health insurance system and increasing disposable incomes, accounts for nearly half of the total pharmaceutical market. Unlike ethical drugs, the nutrition supplements market is dominated by domestic players but the recent restrictions imposed by the State Duma on the promotion of nutritional supplements have retarted the segment's growth.

The report does a comprehensive analysis of the Russian market, encompassing its demographics, structure of health care sector, size of pharma market, and comparative analysis of the market, among others. Also, a brief overview of the major players operating in the market has been given to present the competitive landscape of the market.

Key Findings

The DLO programme, that was one of the main drivers fuelling strong growth, may act as a restraint, owing to the government's recent cost cutting measures.
The Russian pharmaceutical market witnessed a trend where the drugs sales decreased in volume terms but increased in value terms.
There was a growth in the demand for imported drugs in Russia.
Russians are now turning towards expensive drugs with a higher efficacy as compared to the cheaper traditional drugs.

Key Issues Analyzed

Where does the Russian pharmaceutical market stand in comparison to other key global markets?
What is the market size of various segments in the Russian pharmaceutical industry?
What is the proportion of domestic and imported drugs in each segment?
What are the opportunities that will emerge in future for the market?

Research Methodology Used

Information Sources

The information in the report has been taken from various credible sources like books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.

Analysis Methods

The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting and cause and effect analysis.

For the purpose of this report, the Russian pharmaceutical market has been considered to consist of the following segments:

The commercial drugs market;
The state segment (DLO programme and hospital segment); and
The Parapharmaceutical segment (Food Supplements and Cosmetics).

Content

1. Analyst View
2. Global Pharmaceutical Market
- 2.1 Market Size & Growth
- 2.2 Geographical Performance
- 2.3 Leading Therapy Classes
- 2.4 Leading Pharmaceutical Companies
- 2.5 Leading Drugs
3. Russian Demographics & Healthcare Profile
- 3.1 Population
  - 3.1.1 Life Expectancy
  - 3.1.2 Age Breakup
- 3.2 Healthcare Structure
  - 3.2.1 Hospital Beds & Doctors
  - 3.2.2 Healthcare Expenditure
4. Russian Pharmaceutical Market
- 4.1 Market Overview
  - 4.1.1 Market Size & Growth
  - 4.1.2 Comparative Analysis
- 4.2 Commercial Drug Market
  - 4.2.1 Trends
  - 4.2.2 Imported & Domestic Drugs
  - 4.2.3 RX & OTC Drugs
  - 4.2.4 Sales Structure - By ATC Groups
  - 4.2.5 Leading Pharmaceutical Companies
  - 4.2.6 Leading Drugs
  - 4.2.7 Price Analysis
- 4.3 State Segment of Pharmaceutical Market
  - 4.3.1 DLO Reimbursement Programme
    - 4.3.1.1 Imported & Domestic Drugs
    - 4.3.1.2 RX & OTC Drugs
    - 4.3.1.3 Sales Structure - By ATC Groups
    - 4.3.1.4 Leading Pharmaceutical Companies
    - 4.3.1.5 Leading Drugs
  - 4.3.2 Hospital Segment
    - 4.3.2.1 Imported & Domestic Drugs
    - 4.3.2.2 Drugs Demand - By Price
    - 4.3.2.3 Leading Pharmaceutical Companies
    - 4.3.2.4 Leading Drugs
- 4.4 Parapharmaceutical Commercial Market
  - 4.4.1 Nutritional Supplements Market
    - 4.4.1.1 Imported & Domestic Nutritional Supplements
    - 4.4.1.2 Leading Nutritional Supplements
    - 4.4.1.3 Nutritional Supplements Demand - By Price
5. Industry Analysis
- 5.1 Drivers
  - 5.1.1 Ageing Population
  - 5.1.2 Increasing Volume & Sales of Expensive Drugs
  - 5.1.3 Government Support & Funding
  - 5.1.4 Medical Insurance
  - 5.1.5 Increasing Disposable Income
- 5.2 Opportunities
  - 5.2.1 Cardiovascular Drugs
  - 5.2.2 HIV Drugs
  - 5.2.3 High Insulin Demand
  - 5.2.4 Cancer Drugs
  - 5.2.5 Foreign Players
  - 5.2.6 Generics
  - 5.2.7 Clinical Trials Market
- 5.3 Challenges
  - 5.3.1 Declining Population
  - 5.3.2 DLO Crisis
  - 5.3.3 Ineffective Quality Control of Medicines
  - 5.3.4 Drugs Counterfeiting & Weak IPR Protection
6. Future Outlook (2007- 2011)
7. Key Players
- 7.1 Sanofi-Aventis
- 7.2 Novartis
- 7.3 Roche Group
- 7.4 Pfizer Inc
- 7.5 AstraZeneca
List of Figures:
- Figure 2-1: Global - Pharmaceutical Market (in Billion US$), 2001-2006
- Figure 2-2: Global - Pharmaceutical Market Growth (%), 2002-2006
- Figure 2-3: Global - Pharmaceutical Market by Region (%), 2006
- Figure 2-4: Global - Leading Pharmaceutical Companies by Sales, Profit before Taxes & Market Capitalization (in Billion US$), 2006
- Figure 3-1: Russia - Population (in Million), 2001-2006
- Figure 3-2: Russia - Life Expectancy of Male & Female (in Years), 2001-2006E
- Figure 3-3: Russia - Population Breakup by Age (%), 2001-2006
- Figure 3-4: Russia - Number of Doctors (per '000 Population), 2001-2006E
- Figure 3-5: Russia - Number of Hospital Beds (per '000 Population), 2001-2006E
- Figure 3-6: Russia - Share of Healthcare Expenditure in GDP (%), 2000-2005E
- Figure 3-7: Russia - Per Capita Healthcare Expenditure* (in US$), 2000-2005E
- Figure 4-1: Russia - Pharmaceutical Market (in Million US$), 2005 & 2006
- Figure 4-2: Russia - Share of Key Segments in Pharmaceutical Market (%), 2005 & 2006
- Figure 4-3: Global - Top Pharmaceutical Markets Retail Sales (in Billion US$), 2006
- Figure 4-4: Global - Top Pharmaceutical Markets Growth in Retail Sales (%), 2006
- Figure 4-5: Global - Top Pharmaceutical Markets Per Capita Drug Consumption (in US$), 2006
- Figure 4-6: Russia - Share of Personal & State Financing in Pharmaceutical Market (%), 2004-2006
- Figure 4-7: Global - Share of State & Personal Financing in Top Pharmaceutical Markets (%), 2006
- Figure 4-8: Russia - Commercial Drug Market (in Million US$), 2005 & 2006
- Figure 4-9: Russia - Trends in Commercial Drugs Market (%), 2006
- Figure 4-10: Russia - Share of Imported & Domestic Drugs in Commercial Drugs Market by Sales Value (%), 2005 & 2006
- Figure 4-11: Russia - Share of Imported & Domestic Drugs in Commercial Drugs Market by Sales Volume (%), 2005 & 2006
- Figure 4-12: Russia - Share of RX & OTC Drugs in Commercial Drugs Market by Sales Value (%), 2005 & 2006
- Figure 4-13: Russia - Share of RX & OTC Drugs in Commercial Drugs Market by Sales Volume (%), 2005 & 2006
- Figure 4-14: Russia - Growth of Major ATC Groups in Commercial Drugs Market (%), 2006
- Figure 4-15: Russia - Price Index for Drugs in Commercial Drugs Market (%), 2005 & 2006
- Figure 4-16: Russia - Price Index for Imported & Domestic Drugs in Commercial Drugs Market (%), 2005 & 2006
- Figure 4-17: Russia - Consumer Price Index (%), 2006
- Figure 4-18: Russia - State Segment of Pharmaceutical Market (in Million US$), 2005 & 2006
- Figure 4-19: Russia - Consumption Value of DLO Programme (in Billion US$), 2005 & 2006
- Figure 4-20: Russia - Share of Imported & Domestic Drugs in the DLO List of Full & Trade Name (%), 2006
- Figure 4-21: Russia - Share of Imported & Domestic Drugs Sales under DLO Programme (%), 2005 & 2006
- Figure 4-22: Russia - Share of RX & OTC Drugs Sales Value under DLO Programme (%), 2005 & 2006
- Figure 4-23: Russia - Share of RX & OTC Drugs Sales Volume under DLO Programme (%), 2005 & 2006
- Figure 4-24: Russia - Share of ATC Groups Sales under DLO Programme (%), 2005 & 2006
- Figure 4-25: Russia - Share of Imported & Domestic Drugs Sales Value under Hospital Segment (%), 2005 & 2006
- Figure 4-26: Russia - Share of Imported & Domestic Drugs Sales Volume under Hospital Segment (%), 2005 & 2006
- Figure 4-27: Russia - Drugs Demand by Price under Hospital Segment (%), 2005 &2006
- Figure 4-28: Russia - Parapharmaceutical Market (in Million US$), 2005 & 2006
- Figure 4-29: Russia - Nutritional Supplements Market (in Million US$), 2005 & 2006
- Figure 4-30: Russia - Nutritional Supplements Market Volume (in Million Units), 2005 & 2006
- Figure 4-31: Russia - Share of Imported & Domestic Nutritional Supplements Sales Value & Volume (%), 2006
- Figure 4-32: Russia - Imported Nutritional Supplements Breakup by Country (%), 2006
- Figure 4-33: Russia - Imported & Domestic Nutritional Supplements Demand by Price (%), 2006
- Figure 5-1: Russia - Percentage of Population above 65 Years of Age (2001-2006)
- Figure 5-2: Russia - Pharmaceutical Market Growth by Segment (%), 2006
- Figure 5-3: Russia - Personal Disposable Income (in Billion US$), 2001-2006E
- Figure 5-4: Russia - Deaths from Cardiovascular Diseases in Total Deaths (%), 2005 & 2030F
- Figure 5-5: Russia - Number of HIV Patients (in '000), 2003 & 2005E
- Figure 5-6: Russia - HIV Drugs Import (in Million US$), 2004 & 2005E
- Figure 5-7: Russia - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2003 & 2025F
- Figure 5-8: Russia - Insulin Market (in Million US$), 2006E-2008
- Figure 5-9: Russia - Deaths from Cancer in Total Deaths (%), 2005 & 2030F
- Figure 5-10: Russia - Generic Drugs Market (in Billion Euro), 2006 & 2010F
- Figure 5-11: Russia - Number of Approved Clinical Trials (2001-2006)
- Figure 5-12: Russia - Number of Patients Participating in Clinical Trials (2002 & 2006)
- Figure 5-13: Russia - Forecast for Population (in Million), 2007-2011
- Figure 6-1: Russia - Forecast for Pharmaceutical Market (in Million US$), 2007-2011
List of Tables:
- Table 2-1: Global - Pharmaceutical Market by Region (in Billion US$), 2006
- Table 2-2: Global - Leading Therapy Classes by Sales (in Billion US$), 2006
- Table 2-3: Global - Leading Drugs by Sales (in Billion US$), 2006
- Table 4-1: Russia - Leading Pharmaceutical Companies by Sales (in Million US$), 2005 & 2006
- Table 4-2: Russia - Sales Structure of ATC Groups in Commercial Drugs Market, 2006
- Table 4-3: Russia - Leading Pharmaceutical Companies in Commercial Drugs Market by Sales (in Million US$), 2005 & 2006
- Table 4-4: Russia - Leading Drugs in Commercial Drugs Market by Sales (in Million US$), 2005 & 2006
- Table 4-5: Russia - Sales Structure of ATC Groups under DLO Programme, 2006
- Table 4-6: Russia - Leading Pharmaceutical Companies under DLO Programme by Sales (in Million US$), 2005 & 2006
- Table 4-7: Russia - Leading Drugs under DLO Programme by Sales (in Million US$), 2005 & 2006
- Table 4-8: Russia - Leading Pharmaceutical Companies under Hospital Segment by Sales (in Million US$), 2005 & 2006
- Table 4-9: Russia - Leading Drugs under Hospital Segment by Sales (in Million US$), 2005 & 2006
- Table 4-10: Russia - Leading Nutritional Supplements in Pharmaceutical Market by Sales (in Million US$), 2005 & 2006
- Table 7-1: Sanofi-Aventis - Key Financials (in Million US$), 2004-2006
- Table 7-2: Novartis - Key Financials (in Million US$), 2004-2006
- Table 7-3: Roche Group - Key Financials (in Million CHF), 2004-2006
- Table 7-4: Pfizer Inc - Key Financials (in Million US$), 2004-2006
- Table 7-5: AstraZeneca - Key Financials (in Million US$), 2004-2006